#151432

Anti-CR2 [BU33]

Cat. #151432

Anti-CR2 [BU33]

Cat. #: 151432

Sub-type: Primary antibody

Unit size: 100 ug

Availability: 10-12 weeks

Target: Complement component (3d/Epstein Barr virus) receptor 2 (CR2, CD21)

Class: Monoclonal

Application: FACS ; IHC ; IP ; WB

Reactivity: Human

Host: Mouse

£300.00

This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.

Contributor

Institute: University of Birmingham

Tool Details
Target Details
Applications
Handling
References

Tool Details

*FOR RESEARCH USE ONLY

  • Name: Anti-CR2 [BU33]
  • Alternate name: Complement Component 3d Receptor 2; Epstein-Barr Virus Receptor 2; Complement C3d Receptor; EBV Receptor; C3DR; CD21 Antigen; CVID7; SLEB9; CD21; Cr2; CR
  • Clone: BU33
  • Tool sub type: Primary antibody
  • Class: Monoclonal
  • Purpose: Marker
  • Conjugation: Unconjugated
  • Strain: Balb/c
  • Reactivity: Human
  • Host: Mouse
  • Application: FACS ; IHC ; IP ; WB
  • Description: CR2 is expressed strongly on mature B cells, follicular dentritic cells and weakly on immature thymocytes and T lymphocytes. In B-cell ontogeny, CR2 appears after the pre-B-stage, is maintained during peripheral B-cell development and is lost upon terminal differentiation into plasma cells. CR2 expression is also gradually lost after stimulation of B cells in vitro. CR2 functions as a receptor for C3d, C3dg and iC3b Complement components and for EBV and for IFN alpha. CR2 binds to CD23 and ...
  • Immunogen: HF B1 plasmactyoid cell line, considered to be "late B like"
  • Isotype: IgG1
  • Myeloma used: NS0

Target Details

  • Target: Complement component (3d/Epstein Barr virus) receptor 2 (CR2, CD21)
  • Tissue cell line specificity: Mouse
  • Target background: CR2 is expressed strongly on mature B cells, follicular dentritic cells and weakly on immature thymocytes and T lymphocytes. In B-cell ontogeny, CR2 appears after the pre-B-stage, is maintained during peripheral B-cell development and is lost upon terminal differentiation into plasma cells. CR2 expression is also gradually lost after stimulation of B cells in vitro. CR2 functions as a receptor for C3d, C3dg and iC3b Complement components and for EBV and for IFN alpha. CR2 binds to CD23 and ...

Applications

  • Application: FACS ; IHC ; IP ; WB

Handling

  • Format: Liquid
  • Concentration: 0.9-1.1 mg/ml
  • Unit size: 100 ug
  • Storage buffer: PBS with 0.02% azide
  • Storage conditions: -15° C to -25° C
  • Shipping conditions: Shipping at 4° C

References

  • Mayall et al. 2001. J Comp Pathol. 124(1):83-7. PMID: 11428193.
  • The anti-human CD21 antibody, BU33, identifies equine B cells.
  • Scholssman SF. et al. 1995. Leucocyte Typing V. Oxford University Press. ISBN-13: 978-0192623768
  • Henchoz et al. 1994. Immunology. 81(2):285-90. PMID: 7512529.
  • Stimulation of human IgE production by a subset of anti-CD21 monoclonal antibodies: requirement of a co-signal to modulate epsilon transcripts.
  • Bacon et al. 1993. Eur J Immunol. 23(10):2721-4. PMID: 76...